Navigation Links
Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
Date:9/14/2010

Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its... -- JERUSALEM, September 14, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries, FDA Approval Click to view news release full screen  

Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule

   

Proof of Concept Study for a New Indication of Oral Insulin Capsule for Type 1 Diabetics

JERUSALEM, September 14, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today successful results in an exploratory clinical trial testing the effectiveness of its oral insulin capsule (ORMD-0801) in Type I diabetes patients suffering from uncontrolled diabetes.

In parallel to Oramed's main focus in developing an oral insulin capsule for management of Type II diabetes the company is exploring an application of its oral insulin capsule toward cases of uncontrolled Type I diabetics. Unstable or labile diabetes is characterized by recurrent, unpredictable and dramatic blood glucose swings often linked with irregular hyperglycemia and sometimes serious hypoglycemia affecting Type I diabetes patients. This newly completed exploratory study was a proof of concept study for defining a novel indication for ORMD-0801. The encouraging results justify further clinical development of ORMD-0801 capsule application toward management of uncontrolled diabetes.

"This study marks an impressive milestone for Oramed," says Nadav Kidron, CEO of Oramed Pharmaceuticals. "These results suggest a possible novel and unique indication for our oral insulin product in the treatment of Type I diabetes in addition to our main indication for Type II diabetes."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts: Oramed Pharmaceuticals Inc. Tara Horn Office: +1-646-240-4193 Cell: +972-54-334-4318 Email: tara@oramed.com
'/>"/>

SOURCE Oramed Pharmaceticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
2. Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
3. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
4. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
5. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
6. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
7. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
8. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
9. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
10. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Theravance Biopharma, Inc. (NASDAQ: ... announced the presentation of positive clinical data for ... kinase (JAK) inhibitor designed to be intestinally restricted, ... European Crohn,s and Colitis Organization (ECCO). In a ... its completed Phase 1 study of single-ascending and ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits ... effects allegedly associated with use of the atypical antipsychotic ... Philadelphia Court of Common Pleas, where the ... tort program. According to a notice posted on the ... convene a meeting on March 9, 2017 at 11:00 ...
(Date:2/17/2017)... , Feb. 17, 2017  BioDigital, Inc., ... the partnership of their 3D body mapping technology ... IT.  The new integration will be used to ... interactive model of the human body. BioDigital pilots ... clinicians time, while also increasing the precision of ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume ... Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... can pick and choose from hand-crafted trend-setting designs with smooth animations that will ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... mobility has not kept pace. Enovate Medical has introduced an innovative workstation designed ... years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... brings its educational assistance management solution to the exhibit floor for the ... Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare industry ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... season , Trinity Health and the U.S. Soccer Foundation announced today that they ... underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the ...
Breaking Medicine News(10 mins):